Ravagalimab
- Generic Name
- Ravagalimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050816-56-1
- Unique Ingredient Identifier
- YGF9TW3QZJ
- Background
Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy).
- Associated Conditions
- -
- Associated Therapies
- -
A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT06402513
- Locations
- 🇺🇸
Acpru /Id# 265325, Grayslake, Illinois, United States
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- AbbVie
- Registration Number
- NCT05217472
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht /ID# 214029, Utrecht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath